4.8 Article

Positron Emission Tomography-Guided Photodynamic Therapy with Biodegradable Mesoporous Silica Nanoparticles for Personalized Cancer Immunotherapy

期刊

ACS NANO
卷 13, 期 10, 页码 12148-12161

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.9b06691

关键词

mesoporous silica nanoparticles; cancer immunotherapy; positron emission tomography; photodynamic therapy; neoantigen; vaccine

资金

  1. NIH [HHSN272201300006C, R01AI127070, R01EB022563, R01CA210273, R01 CA223804, U01CA210152]
  2. UM Forbes Institute
  3. Emerald Foundation
  4. Melanoma Research Alliance [348774]
  5. DoD/CDMRP Peer Reviewed Cancer Research Program [W81XWH-16-1-0369]
  6. NSF [1553831]
  7. MTRAC
  8. Directorate For Engineering [1553831] Funding Source: National Science Foundation
  9. Div Of Chem, Bioeng, Env, & Transp Sys [1553831] Funding Source: National Science Foundation

向作者/读者索取更多资源

Photodynamic therapy (PDT) is an effective, noninvasive therapeutic modality against local tumors that are accessible to the source of light. However, it remains challenging to apply PDT for the treatment of disseminated, metastatic cancer. On the other hand, cancer immunotherapy offers a promising approach for generating systemic antitumor immune responses against disseminated cancer. Here we report a multifunctional nanomaterial system for the combination of PDT and personalized cancer immunotherapy and demonstrate their potency against local as well as disseminated tumors. Specifically, we have synthesized uniform and biodegradable mesoporous silica nanoparticles (bMSN) with an average size of similar to 80 nm and large pore size of 5-10 nm for theranostic positron emission tomography (PET)-guided PDT and neoantigen-based cancer vaccination. Multiple neoantigen peptides, CpG oligodeoxynucleotide adjuvant, and photosensitizer chlorin e6 were coloaded into a bMSN nanoplatform, and PET imaging revealed effective accumulation of bMSN in tumors (up to 9.0% ID/g) after intravenous administration. Subsequent PDT with laser irradiation recruited dendritic cells to PDT-treated tumor sites and elicited neoantigen-specific, tumor-infiltrating cytotoxic T-cell lymphocytes. Using multiple murine models of bilateral tumors, we demonstrate strong antitumor efficacy of PDT-immunotherapy against locally treated tumors as well as distant, untreated tumors. Our findings suggest that the bMSN is a promising platform for combining imaging and PDT-enhanced personalized immunotherapy for the treatment of advanced cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据